Clinical trial · Interventional
Real Life Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG
Real Life Prospective Multicentric Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG
NCT04934865CI-TRIAL-00087111REAL-MOOV-LUNGcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluation of patient's proportion, whose management care has been modified at least once and specially by Moovcare® Lung application at 12 and 24 months.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Patients treated for their lung cancer. | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Patients treated for their lung cancer and Moovcare® Lung follow-up.
- interventionNames
- Device: Patients treated for their lung cancer.
Primary outcomes (2)
- measure
- Proportion of patients.
- timeFrame
- 24 months
- description
- Proportion of patients whose care management was modified at least once and specifically by Moovcare® Lung application at months.
- measure
- Proportion of patients.
- timeFrame
- 12 months
- description
- Proportion of patients whose care management was modified at least once and specifically by Moovcare® Lung application at 12 months.
Secondary outcomes (17)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patient with lung cancer at any diagnostic stage and histology. 2. Patient willing to use the follow-up setting with Moovcare® Lung apps. 3. Age ≥ 18 years. 4. Patient received anti-cancer treatment (surgery, chemotherapy, radiation (stereotaxy or not) or radio-chemotherapy association ended less than 12 weeks (Cohort 1 post-treatment); or during maintenance treatment or consolidation by chemotherapy or targeted therapy, or by immunotherapy initiated less than 12 weeks (Cohort 2 during treatment). 5. Imaging tumor evaluation less than 12 weeks showing disease control (response or stability according to RECIST 1.1 criteria). 6. Patient with symptomatic score on Moovcare® Lung apps less than 7. 7. Patient (or relatives) with internet access, a personnal e-mail box and a smartphone. 8. Patient with social security affiliation. 9. Signed informed consent form. Exclusion Criteria: 1. Patient with progression after the first evaluation of initial treatment. 2. Pregnancy and breast-feeding. 3. Patient under tutorship or guardianship. 4. Dementia, mental alteration or psychiatric pathology influencing patient consent procedure and/or protocol observance and study follow-up. 5. Patient enable to protocol follow-up for psychological, social, familial or geographical reasons.
References
Publications (0)
Data not yet available
No reference posted for this study.